BioCentury Innovations (formerly SciBX)
As published Thursday, March 05, 2015
Australian newco Solvanix Pty. Ltd. was founded last month on the basis of two amino acid changes in an antibody. The start-up expanded its early studies showing the altered residues transformed a misbehaving mAb into a viable candidate, and has created a technology for preventing antibody aggregation without incurring immunogenicity. Now the company is looking for biotechs and pharmas to license the technology.
Solvanix believes its strategy can solve common problems across the spectrum of antibody development, from early compound selection where aggregation causes good molecules to be screened out, to formulation of drugs for autoinjectors where the high concentrations and small volumes needed commonly result in protein aggregation.
Cardiologist Philip Sager says the current thinking on preclinical cardiovascular safety involves new ways of looking at ion conductance to replace QT, and might enable or rescue many compounds.
NIH's meeting with G7 health leaders coincided with three announcements about AD funding, and stakeholders are optimistic the field is starting to get some much-needed attention.
A T cell-based fingerprint in the plasma of kidney transplant recipients could identify patients who will develop tolerance and not need immunosuppressive therapy.